Abstract:BACKGROUND:The knowledge of Epidermal growth factor receptor (EGFR) expression in metastases of NSCLC was limited. In receptor-mediated targeted nuclide radiotherapy, tumor cells are killed with delivered radiation and therapeutic efficiency is mainly dependent on the receptor expression. Thus, the level and stability of receptor expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as target. The goal of this study was to evaluate whether EGFR is suitable as target for clinical therapy.METHODS:Expression of EGFR was investigated immunohistochemically in paired samples of lymph node metastases and corresponding NSCLC primary lesions (n = 51). EGFR expression was scored as 0, 1+, 2+ or 3+.RESULTS:Positive (1+, 2+ or 3+) EGFR immunostaining was evident in 36 of 47 (76.6%) analysed NSCLC primary tumors, and in 78.7% of the corresponding lymph node metastases. When EGFR expression is classified as positive or negative, discordance between the primary tumors and the corresponding metastases was observed in 5 cases (10.6%). EGFR overexpression (2+ or 3+) was found in 53.2% (25/47) of the NSCLC primary tumors and 59.6% of the corresponding metastases. Nine out of the 47 paired samples (19.2%) were discordant: Only three patients who had EGFR overexpression in the primary tumors showed EGFR downregulation (0 or 1+) in lymph node metastases, while six patients changed the other way around.CONCLUSIONS:The EGFR expression in the primary tumor and the corresponding metastasis is discordant in about 10% of the patients. When overexpression is considered, the discordance is observed in about 20% of the cases. However, concerning EGFR overexpression in the primary tumors, similar expression in the metastases could be predicted with a reasonably high probability, which is encouraging for testing of EGFR targeted nuclide radiotherapy.

Role of Epidermal Growth Factor Receptor in Tumor Radiotherapy

Role of nuclear epidermal growth factor receptor in tumorigenesis and resistant to treatment

Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation

Epidermal growth factor and its receptor(EGFR)in gastrointestinal tract

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

Progress of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors in the Cancer Therapy

EGFR and Radiosensitization of Tumor Cells

EGFR inhibitors and radiosensitivity of tumor cells

Role of Epidermal Growth Factor Receptor in DNA Damage Repair

Nuclear EGFR:a Potential Target for Radiosensitizer

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Epidermal Growth Factor Receptor Family Tyrosine Kinase and Cancer Therapy

Epidermal Growth Factor Receptor and Its Relationship with Gastric Carcinoma

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Epidermal growth factor receptor: an important target in esophageal cancer

Progression in the mechanisms of EGFR inhibitors combined with radiotherapy

Epigenetic regulation of TGF-β pathway and its role in radiation response

Platelet Derived Growth Factor and Its Receptor and the Radiation Resistance of Tumor Cells

Tumor‑penetrating Peptide Fused EGFR Single‑domain Antibody Enhances Radiation Responses Following EGFR Inhibition in Gastric Cancer.

[Association of Epithermal Growth Factor Receptor Expression and Its Downstream Gene Mutation Status with Radiosensitivity of Colorectal Carcinoma Cell Lines in Vitro].

TGF-beta Signaling in Cancer Radiotherapy